Jawaharlal Nehru Centre for Advanced Scientific Researchers (JNCASR) have developed a small molecule that disrupts the mechanism through which neurons become dysfunctional in Alzheimer's disease (AD). The molecule could be a potential drug candidate to halt or cure the leading cause of dementia (70-80%) worldwide.

In the Alzheimer’s brain, abnormal levels of naturally forming protein clump together to form plaques that collect between neurons and disrupt cell function. This is caused by production and deposition of the amyloid peptide that accumulates in the central nervous system. The multifactorial nature of Alzheimer’s disease (AD) attributed to multifaceted amyloid toxicity has kept researchers from developing effective treatment.

A team of scientists led by Professor T. Govindaraju from Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), an autonomous institute of the Department of Science & Technology, Government of India, designed and synthesized a set of novel small molecules and identified a lead candidate which they found could reduce the toxicity of Amyloid Beta (Aβ) toxicity.

The detailed studies established the molecule called TGR63 as the lead candidate to rescue neuronal cells from amyloid toxicity. Remarkably, the molecule was also found to reduced amyloid burden in the cortex and hippocampus, or a complex part embedded deep into the temporal lobe, thereby reversing cognitive decline. This research has been published recently in the journal Advanced Therapeutics.

Currently available treatments provide only temporary relief, and there are no approved drugs that directly act on the disease mechanisms of Alzheimer's disease. Thus, there is an unmet need to develop drug candidates to halt or cure Alzheimer's disease.

ESIC takes steps to alleviate conditions for women to avail sickness benefit

LIFESTYLE- FOOD: Probiotics, Fermented Dairy Products

Know how sleep helps us learn and remember